Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 197

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2024-201755

Published: 2024

Journal Articles

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Juan Esteban Velez-Hernandez, Mateo Mejia Saldarriaga, Caitlin Unkenholz, Christian A Gordillo, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Markus Y Mapara, Ruben Niesvizky, Ran Reshef, Samuel Yamshon, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2024-209960

Published: 2024

Journal Articles

Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

Sharmilee Nuli, Rajshekhar Chakraborty, Al-Ola Abdallah, Suzanne Lentzsch, Evguenia Ouchveridze, Douglas W Sborov, Amandeep Godara, Brian McClune, Ah-Reum Jeong, Samuel M. Rubinstein, Aaron Goodman, Ghulam Rehman Mohyuddin

Blood (2024) 144 (Supplement 1): 6924.

https://doi.org/10.1182/blood-2024-203731

Published: 2024

Journal Articles

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Rajshekhar Chakraborty, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood (2024) 144 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2024-210478

Published: 2024

Journal Articles

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Michael Sang Hughes, Metodi Balev, Jai Radhakrishnan, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2024) 144 (Supplement 1): 6983.

https://doi.org/10.1182/blood-2024-209301

Published: 2024

Journal Articles

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, J Christine Ye, Samuel M. Rubinstein, Sascha Tuchman, Eben I Lichtman

Blood (2024) 144 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2024-210587

Published: 2024

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Blood (2024) 144 (Supplement 1): 4681.

https://doi.org/10.1182/blood-2024-206496

Published: 2024

Journal Articles

Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Jing Fu, Huihui Ma, Shirong Li, Michael Sang Hughes, Gavreel Kalantarov, Guifen Liu, Markus Mapara, Suzanne Lentzsch

Blood (2024) 144 (Supplement 1): 360.

https://doi.org/10.1182/blood-2024-202091

Published: 2024

Journal Articles

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 287.

https://doi.org/10.1182/blood-2024-202589

Published: 2024

Journal Articles

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Caitlin Unkenholz, Mateo Mejia Saldarriaga, Esther Ortega, Jorge Monge, Christian A Gordillo, Juan Esteban Velez-Hernandez, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2024-210365

Published: 2024

Journal Articles

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T Mckay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin H van Vliet, David S. Siegel, Saad Z. Usmani, Frits van Rhee

Blood (2024) 144 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2024-209903

Published: 2024

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, Meghan Sise, Elizabeth Shelton, Emily Simone, Naomi Sender, Sherley Mejia, Shayan Shirazayan

Blood (2024) 144 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2024-210308

Published: 2024

Journal Articles

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Muhamed Baljevic, Nizar J. Bahlis, Rami Kotb, Gary J. Schiller, Brea Lipe, Sumit Madan, Heather J. Sutherland, Suzanne Lentzsch, Natalie Callander, Noa Biran, Dane Van Domelen, Tomer Mark, Darrell White

Blood (2024) 144 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2024-208086

Published: 2024

Journal Articles

Contemporary Multiple Myeloma Treatment Patterns Among HCPs and Concordance with Expert Recommendations: Analysis of an Interactive Online Decision Support Tool

Kelly G Brandt, Kristen Rosenthal, Shaji Kunnathu Kumar, Suzanne Lentzsch, Sagar Lonial, Saad Z Usmani, Timothy A. Quill, Joseph R. Mikhael

Blood (2023) 142 (Supplement 1): 7284.

https://doi.org/10.1182/blood-2023-180957

Published: 2023

Journal Articles

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Blood (2023) 142 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2023-190226

Published: 2023

Journal Articles

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Daniel T Peters, Jacob Amburn, Sascha Tuchman, Eben I Lichtman, Christopher Edward Jensen, Koyal Jain, Suzanne Lentzsch, Rajshekhar Chakraborty, Divaya Bhutani, Samuel M Rubinstein

Blood (2023) 142 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2023-189341

Published: 2023

NARROW

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis

Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Contemporary Multiple Myeloma Treatment Patterns Among HCPs and Concordance with Expert Recommendations: Analysis of an Interactive Online Decision Support Tool

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only